My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 125

    1.

    A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

    Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA.

    Diabetes. 2005 Jun;54(6):1763-9.PMID: 15919798 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

    Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA.

    N Engl J Med. 2002 May 30;346(22):1692-8.PMID: 12037148 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

    Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group.

    Clin Immunol. 2009 Aug;132(2):166-73. Epub 2009 May 14.PMID: 19443276 [PubMed - indexed for MEDLINE]Related articles

    4.

    Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

    Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L.

    N Engl J Med. 2005 Jun 23;352(25):2598-608.PMID: 15972866 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

    Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA.

    J Clin Invest. 2003 Feb;111(3):409-18.PMID: 12569167 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Insulin secretion in type 1 diabetes.

    Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC.

    Diabetes. 2004 Feb;53(2):426-33.PMID: 14747294 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus.

    Crinó A, Schiaffini R, Ciampalini P, Suraci MC, Manfrini S, Visalli N, Matteoli MC, Patera P, Buzzetti R, Guglielmi C, Spera S, Costanza F, Fioriti E, Pitocco D, Pozzilli P; IMDIAB Group.

    J Pediatr Endocrinol Metab. 2005 Aug;18(8):749-54.PMID: 16200840 [PubMed - indexed for MEDLINE]Related articles

    8.

    Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.

    Bisikirska BC, Herold KC.

    Ann N Y Acad Sci. 2004 Dec;1037:1-9. Review.PMID: 15699486 [PubMed - indexed for MEDLINE]Related articles

    9.

    A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).

    Crinò A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, Suraci C, Pitocco D, Spera S, Corbi S, Matteoli MC, Patera IP, Manca Bitti ML, Bizzarri C, Pozzilli P; IMDIAB group.

    Eur J Endocrinol. 2004 May;150(5):719-24.PMID: 15132730 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.

    Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z.

    Diabetes Metab Res Rev. 2007 May;23(4):286-91.PMID: 17124721 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.

    Schloot NC, Meierhoff G, Lengyel C, Vándorfi G, Takács J, Pánczél P, Barkai L, Madácsy L, Oroszlán T, Kovács P, Sütö G, Battelino T, Hosszufalusi N, Jermendy G.

    Diabetes Metab Res Rev. 2007 May;23(4):276-85.PMID: 17103487 [PubMed - indexed for MEDLINE]Related articles

    12.

    Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.

    Popma SH, Griswold DE, Li L.

    Int Immunopharmacol. 2005 Jan;5(1):155-62.PMID: 15589476 [PubMed - indexed for MEDLINE]Related articles

    13.

    Anti-CD3 antibody MacroGenics Inc.

    Brown WM.

    Curr Opin Investig Drugs. 2006 Apr;7(4):381-8. Review.PMID: 16625825 [PubMed - indexed for MEDLINE]Related articles

    14.

    Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.

    Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D.

    Diabetes Metab Res Rev. 2007 May;23(4):292-8.PMID: 17124720 [PubMed - indexed for MEDLINE]Related articles

    15.

    Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes.

    Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, Schatz D, Vargas A, Rogers D, Schwartz S, Malone J, Krischer J, Maclaren NK.

    Ann N Y Acad Sci. 2004 Dec;1029:260-77.PMID: 15681764 [PubMed - indexed for MEDLINE]Related articles

    16.

    Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?

    Herold KC, Taylor L.

    Immunol Res. 2003;28(2):141-50. Review.PMID: 14610290 [PubMed - indexed for MEDLINE]Related articles

    17.

    Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody.

    Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA.

    Am J Transplant. 2004 Mar;4(3):390-401.PMID: 14961992 [PubMed - indexed for MEDLINE]Related articles

    18.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    19.

    Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala).

    Ablamunits V, Herold KC.

    Hum Immunol. 2008 Nov;69(11):732-6. Epub 2008 Sep 24. Review.PMID: 18817833 [PubMed - indexed for MEDLINE]Related articles

    20.

    Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.

    Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR.

    J Rheumatol. 2002 Sep;29(9):1907-13.PMID: 12233885 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity